TY - JOUR
T1 - Arsenic derivatives in hematologic malignancies
T2 - A role beyond acute promyelocytic leukemia?
AU - Verstovsek, Srdan
AU - Giles, Francis
AU - Quintás-Cardama, Alfonso
AU - Perez, Nichole
AU - Ravandi-Kashani, Farhad
AU - Beran, Miloslav
AU - Freireich, Emil
AU - Kantarjian, Hagop
PY - 2006/12
Y1 - 2006/12
N2 - The importance of arsenic trioxide (As2O3) has been underscored over the last decade due to its efficacy against acute promyelocytic leukemia (APL), a disease in which this agent has been associated with complete hematologic and molecular remission rates of 87% and 83%, respectively. The different molecular mechanisms of action of Asi2O3 suggest its applicability in hematologic malignancies other than APL. However, responses obtained thus far have consisted of improvements in signs and symptoms without the elimination of a given disease. Toxicities derived from As 2O3 are significant but manageable and reversible. However, the risk/benefit ratio of As2O3 in hematologic malignancies other than APL is still unclear. The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes.
AB - The importance of arsenic trioxide (As2O3) has been underscored over the last decade due to its efficacy against acute promyelocytic leukemia (APL), a disease in which this agent has been associated with complete hematologic and molecular remission rates of 87% and 83%, respectively. The different molecular mechanisms of action of Asi2O3 suggest its applicability in hematologic malignancies other than APL. However, responses obtained thus far have consisted of improvements in signs and symptoms without the elimination of a given disease. Toxicities derived from As 2O3 are significant but manageable and reversible. However, the risk/benefit ratio of As2O3 in hematologic malignancies other than APL is still unclear. The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes.
KW - Arsenic trioxide
KW - Hematologic malignancies
KW - Organic arsenic derivatives
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=33845944601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845944601&partnerID=8YFLogxK
U2 - 10.1002/hon.787
DO - 10.1002/hon.787
M3 - Review article
C2 - 16783836
AN - SCOPUS:33845944601
SN - 0278-0232
VL - 24
SP - 181
EP - 188
JO - Hematological Oncology
JF - Hematological Oncology
IS - 4
ER -